"The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD_CAB) composite score at baseline between healthy participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo."
Comments